Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Income from Continuing Operations (2016 - 2025)

Ptc Therapeutics has reported Income from Continuing Operations over the past 14 years, most recently at 1373535000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 1373535000.0 for Q4 2025, down 1384.77% from a year ago — trailing twelve months through Dec 2025 was 555926000.0 (down 42.58% YoY), and the annual figure for FY2025 was 555926000.0, down 42.58%.
  • Income from Continuing Operations for Q4 2025 was 1373535000.0 at Ptc Therapeutics, down from 15896000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for PTCT hit a ceiling of 866562000.0 in Q1 2025 and a floor of 1373535000.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 5 years was 113842500.0 (2021), compared with a mean of 70779450.0.
  • Peak annual rise in Income from Continuing Operations hit 1046.28% in 2025, while the deepest fall reached 1384.77% in 2025.
  • Ptc Therapeutics' Income from Continuing Operations stood at 344461000.0 in 2021, then tumbled by 159.1% to 203583000.0 in 2022, then soared by 408.94% to 628952000.0 in 2023, then tumbled by 114.71% to 92508000.0 in 2024, then tumbled by 1384.77% to 1373535000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 1373535000.0 (Q4 2025), 15896000.0 (Q3 2025), and 64849000.0 (Q2 2025) per Business Quant data.